GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Qualis Innovations Inc (OTCPK:QLIS) » Definitions » Cash And Cash Equivalents

Qualis Innovations (Qualis Innovations) Cash And Cash Equivalents : $0.09 Mil (As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Qualis Innovations Cash And Cash Equivalents?

Qualis Innovations's quarterly cash and cash equivalents increased from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) and increased from Dec. 2023 ($0.00 Mil) to Mar. 2024 ($0.09 Mil).

Qualis Innovations's annual cash and cash equivalents declined from Dec. 2021 ($0.53 Mil) to Dec. 2022 ($0.07 Mil) and declined from Dec. 2022 ($0.07 Mil) to Dec. 2023 ($0.00 Mil).


Qualis Innovations Cash And Cash Equivalents Historical Data

The historical data trend for Qualis Innovations's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qualis Innovations Cash And Cash Equivalents Chart

Qualis Innovations Annual Data
Trend Jul06 Jul07 Jul08 Jul09 Jul10 Dec11 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only 0.01 8.32 0.53 0.07 -

Qualis Innovations Quarterly Data
Oct10 Jan11 Apr11 Sep11 Dec11 Mar12 Jun12 Sep12 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.03 - - 0.09

Qualis Innovations Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Qualis Innovations  (OTCPK:QLIS) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Qualis Innovations Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Qualis Innovations's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Qualis Innovations (Qualis Innovations) Business Description

Traded in Other Exchanges
N/A
Address
225 Wilmington West Chester Pike, Suite 200, No.145, Chadds Ford, PA, USA, 19317
Qualis Innovations Inc. is the holding company of mPathix Health, Inc. The company is focused on the development, production, and distribution of multi-modal pain management and Central Nervous System related solutions. It develops pain management products using a modality agnostic, virtual operating model. The company is developing a product designed to address the unmet needs of patients who seek alternatives to traditional pain medications and interventions or adjunctive therapies to their current treatment regimen.
Executives
Bin Wang director 112 RICO DR. NORTH, MORGANVILLE NJ 07751